Skip to main content

idorsia Value Stock - Dividend - Research Selection

Idorsia Ltd

ISIN: CH0363463438, WKN: A2DTEB

Market price date: 21.01.2022
Market price: 21,38 CHF

Idorsia Ltd Fundamental data and company key figures of the share

Annual reports in CHF
Key figures 13-09-2021
Cash flow
Net operating cash flow -364.667.000
Capital Expenditures -9.266.000
Free cash flow -373.932.992
Balance sheet
Total Equity 585.483.000
Liabilities & Shareholders equity 1.435.360.000
Income statement
Net income -444.791.000
Eps (diluted) -2,672
Diluted shares outstanding 166.447.000
Net sales/revenue 71.758.000

Fundamental ratios calculated on: 21-01-2022

Key figures 21-01-2022
Cash flow
P/C -9,76
P/FC -9,52
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization3.645.397.248,00 USD
Raw Data SourceIFRS in Millionen CHF
Stock Split2020-10-13,1585.000000/1564.000000

Description of the company

Idorsia Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; ReveraGen to research and co-develop vamorolone, a non-hormonal steroid modulator for the treatment of duchenne muscular dystrophy; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Antares Pharma, Inc. for the development of a self- administered drug device product for Selatogrel; and Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase 1 clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,